Elenagen™, a novel DNA plasmid therapy that previously demonstrated high clinical benefit and low toxicity in cancer patients, has now shown significant promise in alleviating chronic pain demonstrating a 90% success rate. In a peer-reviewed study published in Frontiers in Veterinary Science (DOI: 10.3389/fvets.2025.1519881), Elenagen reduced osteoarthritis pain scores in companion dogs. Because the same pro-inflammatory cytokine loop drives osteoarthritis and other chronic pain states, the findings offer a promising translational signal for non opioid pain medicine.
In the open‑label trial of 17 dogs aged 4–13 years, 90 percent achieved at least a one‑point drop in Pain Severity Score and a two‑point drop in Pain…
Disclaimer
We strive to uphold the highest ethical standards in all of our reporting and coverage. We 5guruayurveda.com want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
Website Upgradation is going on. For any glitch kindly connect at 5guruayurveda.com
